Mepolizumab in eosinophilic disorders

被引：1
|
作者：
Abonia, J. Pablo [2 ]
Putnam, Philip E. [1 ]
机构：
[1] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Gastroenterol Hepatol & Nutr,Coll Med, Cincinnati, OH 45229 USA
[2] Univ Cincinnati, Coll Med, Div Allergy & Immunol, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA
来源：
EXPERT REVIEW OF CLINICAL IMMUNOLOGY | 2011年 / 7卷 / 04期
关键词：
anti-IL-5; eosinophilic gastrointestinal disorders; eosinophils; human; IL-5; mepolizumab; RECOMBINANT HUMAN INTERLEUKIN-5; HUMANIZED MONOCLONAL-ANTIBODY; CHURG-STRAUSS-SYNDROME; IDIOPATHIC HYPEREOSINOPHILIC SYNDROME; INFLAMMATORY-BOWEL-DISEASE; AIRWAY HYPERRESPONSIVENESS; CLINICAL CHARACTERISTICS; DIFFERENTIATION FACTOR; IMATINIB MESYLATE; ESOPHAGITIS;
D O I：
10.1586/ECI.11.27
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Mepolizumab (Bosatria (R), GlaxoSmithKline) is a biologic agent developed to treat asthma. It represents a humanized monoclonal antibody of IgG1 kappa type, which targets human IL-5 and thus prevents its interaction with the alpha-chain of the IL-5 receptor. To date, it has not been approved for use in any eosinophil-related disorder; however, several studies have suggested some therapeutic benefit across a spectrum of eosinophil-related disorders. This article evaluates the currently available preclinical and clinical studies, and the impact of mepolizumab against a variety of eosinophilic disorders.
引用
收藏
页码：411 / 417
页数：7
相关论文
共 50 条
  • [1] Mepolizumab for the treatment of severe eosinophilic asthma
    Poulakos, Mara N.
    Cargill, Shawna M.
    Waineo, Melissa F.
    Wolford, Allen L., Jr.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2017, 74 (13) : 963 - 969
  • [2] Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis
    Ennis, Daniel
    Lee, Jason Kihyuk
    Pagnoux, Christian
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (07) : 617 - 630
  • [3] Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis
    McBrien, C. N.
    Menzies-Gow, A.
    DRUGS OF TODAY, 2018, 54 (02) : 93 - 101
  • [4] Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
    Yancey, Steven W.
    Ortega, Hector G.
    Keene, Oliver N.
    Bradford, Eric S.
    ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY, 2019, 15 (01):
  • [5] Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis
    Stein, Miguel L.
    Collins, Margaret H.
    Villanueva, Joyce M.
    Kushner, Jonathan P.
    Putnam, Philip E.
    Buckmeier, Bridget K.
    Filipovich, Alexandra H.
    Assa'ad, Amal H.
    Rothenberg, Marc E.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 118 (06) : 1312 - 1319
  • [6] Clinical usefulness of mepolizumab in severe eosinophilic asthma
    Menzella, Francesco
    Lusuardi, Mirco
    Montanari, Gloria
    Galeone, Carla
    Facciolongo, Nicola
    Zucchi, Luigi
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2016, 12 : 907 - 916
  • [7] Mepolizumab for the reduction of exacerbations in severe eosinophilic asthma
    Russell, Richard
    Brightling, Christopher
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2016, 10 (06) : 607 - 617
  • [8] MEPOLIZUMAB IN SEVERE EOSINOPHILIC ASTHMA
    Shahzad, Q.
    Zaheer, M.
    CHEST, 2020, 157 (06) : 275A - 275A
  • [9] Mepolizumab for severe eosinophilic asthma
    Robinson, Douglas S.
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2013, 7 (01) : 13 - 17
  • [10] Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis
    Steinfeld, Jonathan
    Bradford, Eric S.
    Brown, Judith
    Mallett, Stephen
    Yancey, Steven W.
    Akuthota, Praveen
    Cid, Maria C.
    Gleich, Gerald J.
    Jayne, David
    Khoury, Paneez
    Langford, Carol A.
    Merkel, Peter A.
    Moosig, Frank
    Specks, Ulrich
    Weller, Peter F.
    Wechsler, Michael E.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (06) : 2170 - 2177
12345